Estimates of total body iron indicate 19 mg and 38 mg oral iron are equivalent for the mitigation of iron deficiency in individuals experiencing repeated phlebotomy

Iron deficiency anemia is a common clinical condition often treated with tablets containing 65 mg of elemental iron. Such doses can elicit gastrointestinal side effects lowering patient compliance. Oral iron supplements also increase hepcidin production causing decreased fractional absorption of sub...

Full description

Saved in:
Bibliographic Details
Published in:American journal of hematology 2017-09, Vol.92 (9), p.851-857
Main Authors: Bialkowski, Walter, Kiss, Joseph E., Wright, David J., Cable, Ritchard, Birch, Rebecca, D'Andrea, Pam, Bryant, Barbara J., Spencer, Bryan R., Mast, Alan E.
Format: Article
Language:English
Subjects:
Anemia
Anemia, Iron-Deficiency - blood
Anemia, Iron-Deficiency - drug therapy
Anemia, Iron-Deficiency - etiology
Blood & organ donations
Blood donors
Dietary supplements
Female
Ferrous Compounds - administration & dosage
Hematology
Hemoglobin
Hepcidin
Humans
Iron
Iron - blood
Iron deficiency
Male
Nutrient deficiency
Phlebotomy - adverse effects
Postoperative Complications - blood
Postoperative Complications - drug therapy
Tablets
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Iron deficiency anemia is a common clinical condition often treated with tablets containing 65 mg of elemental iron. Such doses can elicit gastrointestinal side effects lowering patient compliance. Oral iron supplements also increase hepcidin production causing decreased fractional absorption of subsequent doses. Frequent blood donors often become iron deficient. Therefore, they were enrolled in a two‐year study involving continued blood donations and randomization to receive no pill, placebo, 19, or 38 mg ferrous gluconate for 60 days. Total body iron (TBI) did not change for the subset of donors in the no pill and placebo groups who completed both enrollment and final visits (P = .21 and P = .28, respectively). However, repeated measures regression analysis on the complete dataset estimated a significant decrease in TBI of 52 mg/year for the placebo and no pill groups (P = .001). The effects of 19 and 38 mg iron supplementation on TBI were indistinguishable (P = .54). TBI increased by 229 mg after the initial 60 days of iron supplementation (P 
ISSN:0361-8609
1096-8652
DOI:10.1002/ajh.24784